

Supplemental legends

Supplemental Figure S1. Residual gastrin expression in mouse adult alpha cells. (A) Immunofluorescence (IF) colocalisation of gastrin and glucagon (Glu), in the pancreas of adult wild-type mice (n = 3 mice) using the Santa Cruz antibody directed against gastrin without (no peptide) or with (peptide) the corresponding blocking peptide (Santa Cruz, reference sc-7783 P). The incubation of the gastrin antibody with the blocking peptide abrogate the signal raised by the gastrin peptide. Scale bars = 20 μ m. (B) IF colocalisation of Progastrin and glucagon (Glu), in the pancreas of adult wild-type mice (n = 3 mice). Scale bars = 20 μ m. (C) Representative RT-PCR on RNA from wild-type C57BL/6J mouse islet preparation, liver, proximal duodenal mucosa, and stomach antral mucosa (antrum). *Gastrin* mRNA was detected in all islet sample preparation tested (data not shown, n = 10 different mice). CCK: cholecystinin; GIP: Glucose-dependent insulintropic peptide; TBP: TATA BOX-BINDING PROTEIN.

Supplemental Figure S2. Gastrin is not expressed in somatostatin⁺ cells at P0. Representative IF stainings for gastrin and somatostatin at birth in wild-type mouse pancreas (n = 3 mice). Scale-bar = 25 μ M

Supplemental Figure S3. (A) IHC stainings for the indicated factors in 12-month-old Control and *PancEndoMen1* KO mice (related to figure 3A). Note that the tumor located on the right express gastrin whereas the tumor on the left does not. Scale bars = 50 μ M. (B) Graph representing the percentage of Ki67⁺ tumoral cells in insulin⁺gastrin⁻ and insulin+gastrin+ tumors counted from both 12-month-old *β Men1* KO and *PancEndoMen1* KO mice. n \geq 5 tumors. (C-D) Results of gastrin measurements from *β Men1* KO (C) or *PancEndoMen1* KO (D) mice \geq 12 months of age, n \geq 3 mice for each group